Renown Pharma

Renown Pharma is obtaining regulatory approval for a patented sublingual formulation of apomorphine for the treatment of severe uncontrollable motor fluctuations in late-stage Parkinson's disease. Apomorphine is considered the "Gold Standard" treatment for late-stage Parkinson's patients but it is currently administered as either a painful, highly acidic subcutaneous injection or via infusion. Renown has a simple, patented dual chamber device with pH3 stabilised apomorphine in one chamber and a neutralizing agent and absorption enhancer in the other. At the site of administration, which is under the tongue, the two liquids are combined to create a pH7 neutral liquid which is absorbed via the buccal mucosa.